Evolution of analytical tools and techniques for hematopoietic cell therapy manufacture

Cell & Gene Therapy Insights 2022; 8(5), 621–626

DOI: 10.18609/cgti.2022.095

Published: 15 June 2022
Riccardo Biavasco

David McCall, Editor, Cell & Gene Therapy Insights, talks to Riccardo Biavasco, Senior Scientist at bluebird bio

Riccardo Biavasco obtained his PhD in Cellular and Molecular Biology in 2018 working at the Telethon Institute for Gene Therapy, where he designed and generated a humanized mouse model for myeloid inflammatory neoplasms and characterized the effects of aberrant cellular senescence in hematopoietic stem and progenitor cells. In 2019 Riccardo joined bluebird bio analytical development group, where he coordinates the development of characterization assays for hematopoietic stem cell drug products and he is responsible for the interactions with regulatory agencies regarding drug product characterization assays.